Dr. Frank,

I apologize for not appreciating your time frame with Cytodyn. I was not able to listen to the Q&A but certainly cannot deny that aggressive questioning would be a challenge for which management is currently not prepared.

I do not have previous experience with OTC biotechs, so I don't know how to rate their performance on these calls.

As you have been here for seven years, you must appreciate that another three months is the blink of an eye.

I expect that most investors expect a transition or significant supplementation of current management going forward, but it certainly seems that approval or EUA in covid is coming in three or four months.

I know that you have been promised HIV approval for years, but the slow struggle does not preclude success. Your observations of the issues facing the company IMO are accurate, but I assume that I am just more bullish about the near term future than many.

Thanks you for the detailed response.